Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An efficient synthetic method and theoretical calculations of olmesartan methyl ether: study of biological function of AT1 antagonism.
Ntountaniotis D, Agelis G, Resvani A, Halabalaki M, Liapakis G, Spyridaki K, Grdadolnik SG, Merzel F, Kostidis S, Potamitis C, Tselios T, Matsoukas J, Skaltsounis LA, Mavromoustakos T. Ntountaniotis D, et al. Among authors: spyridaki k. Comb Chem High Throughput Screen. 2014;17(8):652-62. doi: 10.2174/138620731708140922171503. Comb Chem High Throughput Screen. 2014. PMID: 24875271
The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives.
Agelis G, Resvani A, Durdagi S, Spyridaki K, Tůmová T, Slaninová J, Giannopoulos P, Vlahakos D, Liapakis G, Mavromoustakos T, Matsoukas J. Agelis G, et al. Among authors: spyridaki k. Eur J Med Chem. 2012 Sep;55:358-74. doi: 10.1016/j.ejmech.2012.07.040. Epub 2012 Jul 31. Eur J Med Chem. 2012. PMID: 22889560
Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers.
Agelis G, Resvani A, Koukoulitsa C, Tůmová T, Slaninová J, Kalavrizioti D, Spyridaki K, Afantitis A, Melagraki G, Siafaka A, Gkini E, Megariotis G, Grdadolnik SG, Papadopoulos MG, Vlahakos D, Maragoudakis M, Liapakis G, Mavromoustakos T, Matsoukas J. Agelis G, et al. Among authors: spyridaki k. Eur J Med Chem. 2013 Apr;62:352-70. doi: 10.1016/j.ejmech.2012.12.044. Epub 2013 Jan 2. Eur J Med Chem. 2013. PMID: 23376252 Free article.
Structural-functional analysis of the third transmembrane domain of the corticotropin-releasing factor type 1 receptor: role in activation and allosteric antagonism.
Spyridaki K, Matsoukas MT, Cordomi A, Gkountelias K, Papadokostaki M, Mavromoustakos T, Logothetis DE, Margioris AN, Pardo L, Liapakis G. Spyridaki K, et al. J Biol Chem. 2014 Jul 4;289(27):18966-77. doi: 10.1074/jbc.M113.544460. Epub 2014 May 16. J Biol Chem. 2014. PMID: 24838244 Free PMC article.
Discovery of a stable tripeptide targeting the N-domain of CRF1 receptor.
Liapakis G, Karageorgos V, Andreadelis I, Holz GG, Dermitzaki E, Kordopati GG, Stylos EΚ, Spyridaki K, Poulaki S, Ntountaniotis D, Sakellaris S, Vanioti M, Kostagianni A, Marousis KD, Leonis G, Kokotos G, Venihaki M, Spyroulias GA, Tselios T, Margioris A, Tzakos AG, Mavromoustakos T. Liapakis G, et al. Among authors: spyridaki k. Amino Acids. 2020 Sep;52(9):1337-1351. doi: 10.1007/s00726-020-02895-4. Epub 2020 Sep 29. Amino Acids. 2020. PMID: 32996057 Free PMC article.
GnRH-Gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery.
Karampelas T, Argyros O, Sayyad N, Spyridaki K, Pappas C, Morgan K, Kolios G, Millar RP, Liapakis G, Tzakos AG, Fokas D, Tamvakopoulos C. Karampelas T, et al. Among authors: spyridaki k. Bioconjug Chem. 2014 Apr 16;25(4):813-23. doi: 10.1021/bc500081g. Epub 2014 Apr 3. Bioconjug Chem. 2014. PMID: 24661240
17 results